Featuring work of CURE Grantees Drs. Michelle Olsen and Michelle Theus. This work supports the ideas that astrocytes play a vital role in the progression of epileptogenesis following TBI.
“With such a clear response, we have advanced our planning of the focal epilepsy efficacy study for PRAX-628, expected to begin in the second half of 2024. We extend our thanks to the patients who participated in this PPR study,”
Featuring work from CURE Epilepsy Grantee Dr. Maxime O. Baud. Researchers have developed a new method for triggering and imaging seizures in epilepsy patients, offering physicians the ability to collect real-time data to tailor epilepsy surgery.
Most pregnancies with LCM exposure resulted in healthy live births, and no new medication concerns were identified. These findings should be interpreted with caution, as additional data are needed to fully evaluate the safety profile of LCM in pregnancy.
Study results may have implications for prioritizing future COVID-19 treatments and vaccinations for people with epilepsy. The study shows the importance of characterizing this risk to inform patients and for future health and care planning.
2017 CURE Epilepsy grantee Dr. Jack Parent and his team designed a novel system using human neurons grown in a dish to discover the genes behind focal cortical dysplasia (FCD), a common cause of intractable epilepsy.